一项美国艾滋病毒提供者对合并疾病的艾滋病毒感染者抗逆转录病毒治疗管理的调查。

IF 2.1 4区 医学 Q3 INFECTIOUS DISEASES
Sonya Krishnan, Marina B Martinez Rivera, Christopher K Lippincott, Maunank Shah
{"title":"一项美国艾滋病毒提供者对合并疾病的艾滋病毒感染者抗逆转录病毒治疗管理的调查。","authors":"Sonya Krishnan, Marina B Martinez Rivera, Christopher K Lippincott, Maunank Shah","doi":"10.1186/s12981-025-00724-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e. pregnancy) often necessitate individualized antiretroviral therapy (ART) regimens. This study aimed to characterize United States HIV provider strategies for ART selection when faced with concomitant health conditions.</p><p><strong>Methods: </strong>A survey of US HIV providers was conducted using hypothetical patient cases. Standardized clinical case-vignettes were developed and providers were asked to select their preferred regimen. Eleven cases focused on cardiometabolic syndrome, renal dysfunction, weight gain, and pregnancy.</p><p><strong>Results: </strong>119 providers responded across all cases (with a median 57 responses [interquartile range 55.5-72] per case), and were primarily Infectious Diseases physicians in academic settings from across the continental United States. Bictegravir/tenofovir alafenamide/emtricitabine was most commonly prescribed for three case-scenarios of cardiometabolic disease (62.3%). Diverse regimens were recommended for a case involving weight gain, with 98.5% switching from dolutegravir plus tenofovir alafenamide/emtricitabine, most commonly to doravirine/tenofovir disoproxil fumarate/lamivudine. Dolutegravir-based regimens were selected in case-scenarios of pregnancy (77.3%), with some use of bictegravir/tenofovir alafenamide/emtricitabine (13.6%). For two case-scenarios renal disease with worsening creatinine clearance to < 30 mL/minute, many providers used lamivudine or emtricitabine in fixed-dose combination (43.3%).</p><p><strong>Conclusion: </strong>This study reveals varied ART approaches for people living with HIV and non-infectious conditions, often diverging from standard regimens. While guidelines provide a framework, providers adapt treatment based on patient needs. Further research is crucial to optimize ART management in these complex situations.</p>","PeriodicalId":7503,"journal":{"name":"AIDS Research and Therapy","volume":"22 1","pages":"27"},"PeriodicalIF":2.1000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871835/pdf/","citationCount":"0","resultStr":"{\"title\":\"A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions.\",\"authors\":\"Sonya Krishnan, Marina B Martinez Rivera, Christopher K Lippincott, Maunank Shah\",\"doi\":\"10.1186/s12981-025-00724-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e. pregnancy) often necessitate individualized antiretroviral therapy (ART) regimens. This study aimed to characterize United States HIV provider strategies for ART selection when faced with concomitant health conditions.</p><p><strong>Methods: </strong>A survey of US HIV providers was conducted using hypothetical patient cases. Standardized clinical case-vignettes were developed and providers were asked to select their preferred regimen. Eleven cases focused on cardiometabolic syndrome, renal dysfunction, weight gain, and pregnancy.</p><p><strong>Results: </strong>119 providers responded across all cases (with a median 57 responses [interquartile range 55.5-72] per case), and were primarily Infectious Diseases physicians in academic settings from across the continental United States. Bictegravir/tenofovir alafenamide/emtricitabine was most commonly prescribed for three case-scenarios of cardiometabolic disease (62.3%). Diverse regimens were recommended for a case involving weight gain, with 98.5% switching from dolutegravir plus tenofovir alafenamide/emtricitabine, most commonly to doravirine/tenofovir disoproxil fumarate/lamivudine. Dolutegravir-based regimens were selected in case-scenarios of pregnancy (77.3%), with some use of bictegravir/tenofovir alafenamide/emtricitabine (13.6%). For two case-scenarios renal disease with worsening creatinine clearance to < 30 mL/minute, many providers used lamivudine or emtricitabine in fixed-dose combination (43.3%).</p><p><strong>Conclusion: </strong>This study reveals varied ART approaches for people living with HIV and non-infectious conditions, often diverging from standard regimens. While guidelines provide a framework, providers adapt treatment based on patient needs. Further research is crucial to optimize ART management in these complex situations.</p>\",\"PeriodicalId\":7503,\"journal\":{\"name\":\"AIDS Research and Therapy\",\"volume\":\"22 1\",\"pages\":\"27\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871835/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AIDS Research and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s12981-025-00724-w\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIDS Research and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12981-025-00724-w","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

简化的HIV治疗指南支持整合酶链转移抑制剂(iniss)。然而,非传染性合并症和共同发生的情况(如怀孕)往往需要个体化抗逆转录病毒治疗方案。本研究旨在描述美国艾滋病毒提供者在面对伴随的健康状况时选择抗逆转录病毒治疗的策略。方法:对美国艾滋病毒提供者进行调查,使用假设的患者病例。制定了标准化的临床病例调查,并要求提供者选择他们的首选方案。11例集中于心脏代谢综合征、肾功能不全、体重增加和妊娠。结果:119名医疗服务提供者对所有病例做出了回应(平均57人回应[四分位数范围55.5-72]每个病例),主要是来自美国大陆学术机构的传染病医生。比替格拉韦/替诺福韦阿拉那胺/恩曲他滨最常用于心脏代谢疾病的三种情况(62.3%)。对于体重增加的病例,推荐多种方案,98.5%的患者从多替替韦加替诺福韦阿拉胺/恩曲他滨切换到多多拉韦林/富马酸替诺福韦二氧吡酯/拉米夫定。在妊娠情况下,选择以多替替韦为基础的方案(77.3%),部分使用比替替韦/替诺福韦/恩曲他滨(13.6%)。结论:这项研究揭示了艾滋病毒感染者和非传染性疾病患者的多种抗逆转录病毒治疗方法,通常与标准方案不同。虽然指南提供了一个框架,但提供者根据患者的需要调整治疗。进一步的研究对于优化这些复杂情况下的ART管理至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions.

Introduction: Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e. pregnancy) often necessitate individualized antiretroviral therapy (ART) regimens. This study aimed to characterize United States HIV provider strategies for ART selection when faced with concomitant health conditions.

Methods: A survey of US HIV providers was conducted using hypothetical patient cases. Standardized clinical case-vignettes were developed and providers were asked to select their preferred regimen. Eleven cases focused on cardiometabolic syndrome, renal dysfunction, weight gain, and pregnancy.

Results: 119 providers responded across all cases (with a median 57 responses [interquartile range 55.5-72] per case), and were primarily Infectious Diseases physicians in academic settings from across the continental United States. Bictegravir/tenofovir alafenamide/emtricitabine was most commonly prescribed for three case-scenarios of cardiometabolic disease (62.3%). Diverse regimens were recommended for a case involving weight gain, with 98.5% switching from dolutegravir plus tenofovir alafenamide/emtricitabine, most commonly to doravirine/tenofovir disoproxil fumarate/lamivudine. Dolutegravir-based regimens were selected in case-scenarios of pregnancy (77.3%), with some use of bictegravir/tenofovir alafenamide/emtricitabine (13.6%). For two case-scenarios renal disease with worsening creatinine clearance to < 30 mL/minute, many providers used lamivudine or emtricitabine in fixed-dose combination (43.3%).

Conclusion: This study reveals varied ART approaches for people living with HIV and non-infectious conditions, often diverging from standard regimens. While guidelines provide a framework, providers adapt treatment based on patient needs. Further research is crucial to optimize ART management in these complex situations.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AIDS Research and Therapy
AIDS Research and Therapy INFECTIOUS DISEASES-
CiteScore
3.80
自引率
4.50%
发文量
51
审稿时长
16 weeks
期刊介绍: AIDS Research and Therapy publishes articles on basic science, translational, clinical, social, epidemiological, behavioral and educational sciences articles focused on the treatment and prevention of HIV/AIDS, and the search for the cure. The Journal publishes articles on novel and developing treatment strategies for AIDS as well as on the outcomes of established treatment strategies. Original research articles on animal models that form an essential part of the AIDS treatment research are also considered
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信